Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.

The Journal of infectious diseases - 17 Jan 2026

Hurst Jacklyn R, Addo Mary, Li Abby, Khera Shreya S, Persaud Reva, Bertucci Cassandra, Hummel Misha, Espinosa Oscar Javier Pico, Chan Adrienne K, Walmsley Sharon, Mishra Sharmistha, Tan Darrell H S, Kozak Robert

Abstract excerpt

BACKGROUND: Tecovirimat (TPOXX) is an antiviral authorized for the treatment of mpox infections in Canada, but recent clinical trials found it has no impact on symptom duration. METHODS: We conducted a prospective cohort study of individuals diagnosed with mpox in Toronto, Canada. Skin lesion swabs were collected weekly to quantify infectious monkeypox virus (MPXV) shedding through cell culture. The presence of...

Topics

Join the communities discussing this publication.

Antiviral Agents
Benzamides
Canada
Drug Resistance, Viral
Guanidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 40924858
DOI: 10.1093/infdis/jiaf471
PMCID: PMC12811868

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.PMID 40924858Read ↗

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023Semantic proximity Read ↗

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read ↗

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreakSemantic proximity Read ↗

Resistance to anti-orthopoxviral drug tecovirimat (TPOXX<sup>®</sup>) during the 2022 mpox outbreak in the USSemantic proximity Read ↗

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of CongoSemantic proximity Read ↗

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox OutbreakSemantic proximity Read ↗

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatmentSemantic proximity Read ↗

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment.Semantic proximity Read ↗

Structural insights into tecovirimat antiviral activity and poxvirus resistance.Semantic proximity Read ↗

Mpox in the Post-2022 Era: A Comprehensive Review of Viral Evolution, Host Adaptation, and Clinical ManagementSemantic proximity Read ↗

Genomic Epidemiology of Monkeypox Virus During the 2022 Outbreak in New York CitySemantic proximity Read ↗

Community spread of a human monkeypox virus variant with a tecovirimat resistance-associated mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.